MicroGenDX
Ewald Kreid currently serves as General Manager for Germany, Austria, and Switzerland at Zimmer Biomet and has held various leadership roles in the company, including Vice President of Business Strategy and Commercial Excellence for EMEA and Vice President of Strategy and Business Development. Prior experience includes a tenure at Boston Consulting Group, where Ewald Kreid progressed from Consultant-Principal to Partner from 1998 to 2016. Ewald Kreid began career as a Project Manager at the Institute for Industrial Research from 1995 to 1996. Educational credentials include a Master in Public Administration from Harvard Kennedy School, a Magister in Business Administration from WU (Vienna University of Economics and Business), a Mastere Entrepreneurs from HEC Paris, and earlier education from Theresianum Vienna and Deutsche Schulen in Santiago and Madrid.
This person is not in any teams
This person is not in any offices
MicroGenDX
MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions. MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.